Article

Breast Cancer Chemoprevention: Progress and Controversy

National Surgical Adjuvant Breast and Bowel Project (NSABP), Four Allegheny Center - 5th Floor, Pittsburgh, PA 15212, USA.
Surgical Oncology Clinics of North America (Impact Factor: 1.67). 07/2010; 19(3):463-73. DOI: 10.1016/j.soc.2010.03.005
Source: PubMed

ABSTRACT The chemoprevention of breast cancer using pharmacologic agents has had substantial clinical success. Randomized clinical trials evaluating selective estrogen-receptor modulators (SERMs) have shown that these agents reduce the incidence of breast cancer by up to 50% in healthy women at increased risk for the development of the disease. SERMs have been of particular value in women with biopsy-proven risk factors, including atypical hyperplasia or lobular carcinoma in situ of the breast. The agents of established value are important options for women today, and efforts are under way to identify additional more effective therapies.

0 Followers
 · 
94 Views
  • Source
    • "Survival rates for breast cancer have greatly increased with significant improvement in surgical technology and therapy regimens over the last three decades, particularly for early-stage breast cancer. However, no effective treatments currently exist for metastatic breast cancer (2,3). As cancer development largely results from the uncontrolled growth of malignant cells, in which cell proliferation surpasses cell death, deregulation of apoptosis, which occurs frequently in a vast majority of cancer types, has become a non-negligible target for anticancer strategies (4,5). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Damnacanthal, an anthraquinone compound, is isolated from the roots of Morinda citrifolia L. (noni), which has been used for traditional therapy in several chronic diseases, including cancer. Although noni has long been consumed in Asian and Polynesian countries, the molecular mechanisms by which it exerts several benefits are starting to emerge. In the present study, the effect of damnacanthal on MCF-7 cell growth regulation was investigated. Treatment of MCF-7 cells with damnacanthal for 72 h indicated an antiproliferative activity. The MTT method confirmed that damnacanthal inhibited the growth of MCF-7 cells at the concentration of 8.2 μg/ml for 72 h. In addition, the drug was found to induce cell cycle arrest at the G1 checkpoint in MCF-7 cells by cell cycle analysis. Damnacanthal induced apoptosis, determined by Annexin V-fluorescein isothiocyanate/propidium iodide (PI) dual-labeling, acridine-orange/PI dyeing and caspase-7 expression. Furthermore, damnacanthal-mediated apoptosis involves the sustained activation of p21, leading to the transcription of p53 and the Bax gene. Overall, the present study provided significant evidence demonstrating that p53-mediated damnacanthal induced apoptosis through the activation of p21 and caspase-7.
    Oncology letters 05/2014; 7(5):1479-1484. DOI:10.3892/ol.2014.1898 · 0.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), is extracted from the plant Curcuma longa. It was recently reported for its anticancer effect on several types of cancer cells in vitro however, the molecular mechanisms of this anticancer effect are not fully understood. In the present study, we evaluated the effects of curcumin on human mammary epithelial carcinoma MCF-7 cells. Cells were treated with curcumin and examined for cell viability by MTT assay. The cells invasion was demonstrated by transwell assay. The binding activity of NF-κB to DNA was examined in nuclear extracts using Trans-AM NF-κB ELISA kit. Western blot was performed to detect the effect of curcumin on the expression of uPA. Our results showed that curcumin dose-dependently inhibited (P < 0.05) the proliferation of MCF-7 cells. Meanwhile, the adhesion and invasion ability of MCF-7 cells were sharply inhibited when treated with different concentrations of curcumin. Curcumin also significantly decreased (P < 0.05) the expression of uPA and NF-κB DNA binding activity, respectively. It is concluded that curcumin inhibits the adhesion and invasion of MCF-7 cells through down-regulating the protein expression of uPA via of NF-κB activation. Accordingly, the therapeutic potential of curcumin for breast cancer deserves further study.
    Molecular Biology Reports 09/2011; 39(4):4803-8. DOI:10.1007/s11033-011-1273-5 · 1.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemoprevention and prophylactic surgery. In this article, we focus on chemoprevention. There are three chemoprevention agents available to reduce breast cancer risk: tamoxifen, raloxifene and exemestane. In this article, we summarize the major randomized clinical trials investigating the use of these agents in the chemoprevention setting. Randomized controlled trials have shown that these agents can reduce breast cancer incidence, but the potential risks of these agents and their impact on quality of life should also be carefully considered. Indeed, it is always important to keep in mind that chemoprevention targets asymptomatic women, and therefore the decision to embark on this strategy should never be taken lightly.
    Expert Review of Anti-infective Therapy 02/2012; 12(2):223-8. DOI:10.1586/era.11.206 · 2.28 Impact Factor
Show more

Preview

Download
2 Downloads
Available from